AstraZeneca signs up to $247M AI antibody discovery deal with Absci
What's happening? Absci and AstraZeneca have agreed a collaboration worth up to $247 million to design a new antibody-based cancer medicine, first reported by the Financial Times on 29 October 2026. AstraZeneca will pay Absci an upfront fee plus research funding, milestone payments and royalties on future sales. Absci will use its generative AI Drug Creation platform to design an improved antibody against an undisclosed cancer target, aiming for properties such as stronger target binding, better safety and easier manufacturing.
Why it matters: The deal extends Absci's push to turn "de novo" antibody design — creating new antibodies from scratch with AI, rather than screening libraries of existing ones — into a repeatable service for big pharma. In October 2026 Absci said it had become the first company to create and validate antibodies this way using "zero-shot" generative AI. The company argues the approach can cut the time from lead to clinic from as long as six years to 18–24 months. The AstraZeneca collaboration follows Absci's $650 million dermatology-focused AI discovery partnership with Almirall announced a few weeks earlier, and comes alongside its internal pipeline led by ABS-101, a potential best-in-class TL1A antagonist. AstraZeneca has also become one of Absci's listed partners alongside Merck and AMD.
Read more: Pharmaphorum, 29 October 2026 · Financial Times, 29 October 2026